<SEC-DOCUMENT>0001157523-11-002296.txt : 20110427
<SEC-HEADER>0001157523-11-002296.hdr.sgml : 20110427
<ACCEPTANCE-DATETIME>20110427072024
ACCESSION NUMBER:		0001157523-11-002296
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110426
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110427
DATE AS OF CHANGE:		20110427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		11781682

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a6698774.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <hr style="width: 100%; height: 2.0 pt; color: #000000; text-align: center">


    <p style="text-align: center">
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt"><b>WASHINGTON,
      D.C. 20549</b></font><br><br><br><font style="font-size: 16pt; font-family: Times New Roman"><b>FORM
      8-K</b></font><br><br><br><font style="font-size: 12pt"><b>CURRENT REPORT</b></font><b><font style="font-size: 12pt"><br style="font-size: 12pt"></font></b><font style="font-size: 12pt">Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of 1934</font><font style="font-size: 12pt"><br style="font-size: 12pt"></font><br><font style="font-size: 12pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): April 26, 2011</font><br><br><br><font style="font-size: 16pt"><b>Anika
      Therapeutics, Inc.</b></font><br>(Exact name of registrant as specified
      in its charter)
    </p>
    <p style="text-align: center">

    </p>
<div style="text-align:left">
    <table style="width: 100%; font-family: Times New Roman; font-size: 12pt; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 36%; padding-left: 0.0px; text-align: center" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Massachusetts</b>
          </p>
        </td>
        <td style="width: 31%; white-space: nowrap; padding-left: 0.0px; text-align: center; padding-right: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>000-21326</b>
          </p>
        </td>
        <td style="width: 33%; white-space: nowrap; padding-left: 0.0px; text-align: center; padding-right: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>04-3145961</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 36%; padding-left: 0.0px; text-align: center" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or other jurisdiction<br>of incorporation)
          </p>
        </td>
        <td style="width: 31%; padding-left: 0.0px; text-align: center" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Commission File<br>Number)
          </p>
        </td>
        <td style="width: 33%; padding-left: 0.0px; text-align: center" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (I.R.S. Employer<br>Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
<div style="text-align:left">
    <table style="width: 100%; font-family: Times New Roman; font-size: 12pt; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 40%; padding-left: 0.0px; text-align: center" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>32 Wiggins Avenue </b><br><b>Bedford, Massachusetts</b>
          </p>
        </td>
        <td style="width: 27%; padding-left: 0.0px; text-align: center" valign="bottom">
          &#160;
        </td>
        <td style="width: 33%; white-space: nowrap; padding-left: 0.0px; text-align: center; padding-right: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <br>
            <b>01730</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; padding-left: 0.0px; text-align: center" valign="top">
          (Address of Principal Executive Offices)
        </td>
        <td style="width: 27%">

        </td>
        <td style="width: 33%; padding-left: 0.0px; text-align: center" valign="top">
          (Zip Code)
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt">Registrant's Telephone Number, Including
      Area Code: </font><font style="font-size: 12pt"><b>(781) 457-9000</b></font><font style="font-size: 12pt"><br style="font-size: 12pt"></font><font style="font-size: 12pt"><br style="font-size: 12pt"></font><font style="font-size: 12pt"><b>N/A</b></font><font style="font-size: 12pt"><br style="font-size: 12pt"></font><font style="font-size: 12pt">(Former
      name or former address, if changed since last report)</font>
    </p>
    <p style="text-align: center">

    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 12pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligations of the registrant under
      any of the following provisions:</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-size: 12pt">
      </font><font style="font-family: Times New Roman; font-size: 12pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-size: 12pt">
      </font><font style="font-family: Times New Roman; font-size: 12pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-size: 12pt">
      </font><font style="font-family: Times New Roman; font-size: 12pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act </font><br><font style="font-family: Times New Roman; font-size: 12pt">(17
      CFR 240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-size: 12pt">
      </font><font style="font-family: Times New Roman; font-size: 12pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act </font><br><font style="font-family: Times New Roman; font-size: 12pt">(17
      CFR 240.13e-4(c))</font><br><br>
    </p>
    <hr style="width: 100%; color: #000000; height: 2.0 pt; text-align: center">


    <p>
      <br>
      <br>

    </p>
    <div style="width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p>
      <b>Item 8.01 &#160;&#160;&#160;&#160;Other Events.</b>
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt; font-family: Times New Roman; text-align: justify">
      &#160;&#160;&#160;&#160;&#160;On April 26, 2011, Anika Therapeutics, Inc. (the &#8220;Company&#8221;) issued
      a press release announcing certain developments relating to the
      previously disclosed patent infringement lawsuit filed by Genzyme
      Corporation with respect to the Company&#8217;s Monovisc product.&#160;&#160;A copy of
      the press release is attached hereto as Exhibit 99.1 and is incorporated
      herein by reference.
    </p>
    <p>
      <br>
      <br>
      <b>Item 9.01 &#160;&#160;&#160;Financial Statements and Exhibits.</b>
    </p>
    <p style="white-space: nowrap">
      (d)&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;Exhibits.
    </p>
    <p style="white-space: nowrap">
      99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release of Anika Therapeutics, Inc., dated April 26,
      2011.
    </p>
    <p>

    </p>
    <p>

    </p>
    <div style="width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <u><font style="font-family: Times New Roman; font-size: 10pt">SIGNATURES</font></u><br>
    </p>
    <p style="text-indent: 60.0px; font-size: 10pt; font-family: Times New Roman">
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p>

    </p>
<div style="text-align:left">
    <table style="width: 100%; font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 52%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" valign="top" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            ANIKA THERAPEUTICS, INC.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 52%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" valign="top" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 52%">

        </td>
        <td colspan="2">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 52%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Date:&#160;April 26, 2011
          </p>
        </td>
        <td style="width: 3%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left" valign="top">
          By:
        </td>
        <td style="width: 45%; border-bottom: solid black 1.0pt; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Kevin W. Quinlan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 52%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" valign="top" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Name: Kevin W. Quinlan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 52%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" valign="top" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Title: Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      <br>
      <br>
      <br>
      <br>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a6698774ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Anika
      Therapeutics Comments on Patent Litigation</b></font>
    </p>
    <p>
      BEDFORD, Mass.--(BUSINESS WIRE)--April 26, 2011--<b>Anika Therapeutics,
      Inc. </b>(Nasdaq: ANIK), a leader in products for tissue protection,
      healing and repair, based on hyaluronic acid (&quot;HA&quot;) technology,
      announced today that Genzyme Corporation has amended its original patent
      infringement lawsuit with respect to Monovisc<sup>TM</sup>, Anika&#8217;s
      single-injection treatment for osteoarthritis of the knee, to include a
      newly issued patent. Genzyme also filed an additional complaint in the
      United States District Court for the District of Massachusetts on April
      26, 2011 that relates to the new patent and which asserts&#160;the same
      claims. Anika intends to continue to vigorously defend the lawsuits and
      the Monovisc product franchise.
    </p>
    <p>
      <b>About Anika Therapeutics, Inc.</b>
    </p>
    <p>
      Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
      manufactures and commercializes therapeutic products for tissue
      protection, healing, repair and regeneration. These products are based
      on hyaluronic acid (HA), a naturally occurring, biocompatible polymer
      found throughout the body. Anika&#8217;s products range from orthopedic/joint
      health solutions led by ORTHOVISC<sup>&#174;</sup>, a treatment for
      osteoarthritis of the knee; to surgical aids in the ophthalmic and
      anti-adhesion fields. The company also offers aesthetic dermal fillers
      for the correction of facial wrinkles. Anika&#8217;s Italian subsidiary, Anika
      S.r.l, provides complementary HA products in orthopedic/joint health and
      anti-adhesion, as well as therapeutics in new areas such as advanced
      wound treatment and ear, nose and throat care. Anika S.r.l.&#8217;s
      regenerative tissue technology advances Anika&#8217;s vision to offer
      therapeutic products that go beyond pain relief to protect and restore
      damaged tissue.
    </p>
    <p>
      <i>The statements made in this press release which are not statements of
      historical fact are forward-looking statements within the meaning of
      Section 27A of the Securities Act of 1933 and Section 21E of the
      Securities Exchange Act of 1934, including, without limitation,
      statements that may be identified by words such as &quot;expectations,&quot;
      &quot;remains,&quot; &quot;focus,&quot; &quot;expected,&quot; &quot;prospective,&quot; &quot;expanding,&quot; &quot;building,&quot;
      &quot;continue,&quot; &quot;progress,&quot; &#8220;plan,&#8221; &quot;efforts,&quot; &quot;hope,&quot; &quot;believe,&quot;
      &quot;objectives,&quot; &quot;opportunities,&quot; &quot;will,&quot; &quot;seek,&quot; &#8220;expect&#8221; and other
      expressions which are predictions of or indicate future events and trends</i>
      <i>do not constitute historical matters and identify forward-looking
      statements.</i> <i>These statements also include those relating to: (i)
      the Company&#8217;s intent to vigorously</i> <i>defend the Genzyme
      Corporation lawsuits and the Monovisc product franchise</i>.<i> These
      statements are based upon the current beliefs and expectations of the
      Company's management and are subject to significant risks, uncertainties
      and other factors.</i> <i>The Company's actual results could differ
      materially from any anticipated future results, performance or
      achievements described in the forward-looking statements as a result of
      a number of factors including: (i) the Company's ability to successfully
      commence and/or complete clinical trials of its products on a timely
      basis or at all, obtain clinical data to support a pre-market approval
      application or timely file and receive FDA or other regulatory approvals
      of its products, or that such approvals will not be obtained in a timely
      manner or without the need for additional clinical trials; (ii) the
      Company's research and product development efforts and their relative
      success, including whether the Company has any meaningful sales of any
      new products resulting from such efforts; (iii) the cost effectiveness
      and efficiency of our manufacturing operations and production planning;
      (iv) the strength of the economies in which the Company operates or will
      be operating, as well as the political stability of any of those
      geographic areas; (v) future determinations by the Company to allocate
      resources to products and in directions not presently contemplated, or
      (vi) the Company&#8217;s ability to launch Monovisc in the U.S., if at all.</i>
      <i>Any delay in receiving any regulatory approvals may adversely affect
      the Company's competitive position.</i> <i>Even if regulatory approvals
      are obtained, there is a risk that meaningful sales of the products may
      not be achieved.</i> <i>There is also a risk that (i) the Company's
      existing distributors or customers will not continue to place orders at
      historical levels or that any of them will seek to modify or terminate
      existing arrangements, (ii) the Company's efforts to enter into
      long-term marketing and distribution arrangements, including with new
      international distributors for Orthovisc and Monovisc, will not be
      successful, (iii) new distribution arrangements will not result in
      meaningful sales of the Company's products, (iv) the Company&#8217;s
      distributors will be unable to achieve performance and sales threshold
      milestones in its distribution agreements, (v) competitive products will
      adversely impact the Company's product sales, (vi) the estimated size(s)
      of the markets which the Company has targeted its products will fail to
      be achieved, (vii) lack of adequate coverage and reimbursement provided
      by governments and other third party payers for our products and
      services could have a material adverse effect on our results of
      operations, or (viii) increased sales of the Company's products,
      including Hyvisc, Orthovisc, or its ophthalmic products, will not
      continue or sales will decrease or not reach historical sales levels, or
      even if such increases occur that such increases will improve gross
      margins, any of which may have a material adverse effect on the
      Company's business and operations.</i> <i>Certain other factors that
      might cause the Company's actual results to differ materially from those
      in the forward-looking statements include those set forth under the
      headings &quot;Business,&quot; &quot;Risk Factors&quot; and &quot;Management's Discussion and
      Analysis of Financial Condition and Results of Operations&quot; in the
      Company's Annual Report on Form 10-K for the year ended December 31,
      2010, as well as those described in the Company's other press releases
      and SEC filings.</i>
    </p>
    <p>
      CONTACT:<br>Anika Therapeutics, Inc.<br>Charles H. Sherwood, Ph.D.,
      CEO,&#160;781-457-9000<br>or<br>Kevin W. Quinlan, CFO,&#160;781-457-9000
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
